Portal de Periódicos da CAPES

Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency

2013; Oxford University Press; Volume: 169; Issue: 2 Linguagem: Inglês

10.1530/eje-12-1057

1479-683X

Stefanie Hahner, Stephanie Burger‐Stritt, Bruno Allolio,

Pituitary Gland Disorders and Treatments

Evaluation of the pharmacokinetics and safety of s.c. hydrocortisone injection for use in adrenal emergency.Single-center, open-label, sequence-randomized, crossover study in a tertiary care center.Twelve patients with chronic Addison's disease. Comparison of hydrocortisone pharmacokinetics after s.c. and i.m. injection (100 mg) and after s.c. administration of sodium chloride (0.9%) respectively at three different visits.maximum serum cortisol (Cmax), time to Cmax (tmax), and time to serum cortisol >36 μg/dl (tserum cortisol >36 μg/dl) after s.c. administration compared with i.m. administration, safety, and patient preference.Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively). Both i.m. and s.c. injections were well tolerated. Eleven (91.7%) patients preferred s.c. injection, whereas one patient did not have any preference.S.c. administration of 100 mg hydrocortisone shows excellent pharmacokinetics for emergency use with only a short delay in cortisol increase compared with i.m. injection. It has a good safety profile and is preferred by patients over i.m. injection.